These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Kostić VS; Marinković J; Svetel M; Stefanova E; Przedborski S Eur J Neurol; 2002 Jan; 9(1):9-14. PubMed ID: 11784369 [TBL] [Abstract][Full Text] [Related]
7. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722 [TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339 [TBL] [Abstract][Full Text] [Related]
9. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease]. Rocha MS; Andrade LA; Ferraz HB; Borges V Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765 [TBL] [Abstract][Full Text] [Related]
10. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
12. Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease. Guerra A; Suppa A; D'Onofrio V; Di Stasio F; Asci F; Fabbrini G; Berardelli A Brain Stimul; 2019; 12(6):1517-1525. PubMed ID: 31217080 [TBL] [Abstract][Full Text] [Related]
13. [Dyskinesia caused by L-DOPA]. Derkinderen P; Vidailhet M Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668 [TBL] [Abstract][Full Text] [Related]
14. Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms. Pietracupa S; Fasano A; Fabbrini G; Sarchioto M; Bloise M; Latorre A; Altieri M; Bologna M; Berardelli A Parkinsonism Relat Disord; 2013 Nov; 19(11):1004-8. PubMed ID: 23890762 [TBL] [Abstract][Full Text] [Related]
15. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Krack P; Pollak P; Limousin P; Hoffmann D; Xie J; Benazzouz A; Benabid AL Brain; 1998 Mar; 121 ( Pt 3)():451-7. PubMed ID: 9549521 [TBL] [Abstract][Full Text] [Related]
16. A comparison of two iatrogenic dyskinesias. Karson CN; Jeste DV; LeWitt PA; Wyatt RJ Am J Psychiatry; 1983 Nov; 140(11):1504-6. PubMed ID: 6137963 [TBL] [Abstract][Full Text] [Related]
18. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Krack P; Pollak P; Limousin P; Benazzouz A; Deuschl G; Benabid AL Brain; 1999 Jun; 122 ( Pt 6)():1133-46. PubMed ID: 10356065 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
20. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Schneider JS; Gonczi H; Decamp E Brain Res; 2003 Nov; 990(1-2):38-44. PubMed ID: 14568327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]